NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DE-20-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical observational studies and clinical trials to be conducted in the DPBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the DPBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase, with a combined total funding period of up to six years.
Notice NOT-MH-19-055 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DE-20-002 from the NIH Guide for Grants and Contracts. The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
Funding Opportunity RFA-CA-20-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research on HIV-associated cancers in low- and middle-income countries (LMICs) through collaborative networks between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. Each application is required to propose between one to three research projects that address questions in one theme that are relevant to the LMICs and the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as population and implementation studies; mechanistic clinical studies that meet NIH's definition of a clinical trial will be allowed. In addition, the proposed networks must include two mandatory cores; an Administrative Core and a Developmental Core. Additional cores such as Shared Resource cores may be included as appropriate for the needs of the projects.
Funding Opportunity RFA-HL-20-029 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.
Funding Opportunity RFA-AG-20-033 from the NIH Guide for Grants and Contracts. The NIA Behavioral and Social Research LEaders in Alzheimers Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from individuals with diverse backgrounds. NIA encourages applications on a variety of AD/ADRD topics in which behavioral and social research can contribute, such as dementia care, dementia caregiver research, cognitive and dementia epidemiology, behavioral and social pathways of AD/ADRD, early psychological changes preceding AD/ADRD, prevention of AD/ADRD, and disparities in AD/ADRD or dementia-related outcomes.
Notice NOT-AG-20-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-008 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-007 from the NIH Guide for Grants and Contracts
Notice NOT-HG-20-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-005 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-005 from the NIH Guide for Grants and Contracts
Notice NOT-HG-20-004 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-009 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-044 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-059 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage, sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.
Notice NOT-HS-19-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NR-20-001 from the NIH Guide for Grants and Contracts. This RFA encourages research to promote a greater understanding of the challenges faced by rural population groups, for the development (or adoption/adaptation) of evidence-based interventions that can reduce the health risks faced by rural Americans. Both prevention and treatment interventions are needed to address rural health issues. Prevention strategies should address and measure reductions in risk factors and enhancement of protective factors, while treatment approaches would seek to measure and address amelioration of health in individuals living with existing conditions. To accomplish these goals, the research community will be encouraged to use a wide range of culturally appropriate methodological approaches that can enhance access to and acceptability of interventions in rural settings, such as telehealth and community-based prevention research, where appropriate. It is our hope that research supported under this RFA will contribute to our knowledge of the sustainability of health promotion strategies in rural settings.
Funding Opportunity RFA-ES-20-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct Phase II (R44) and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop novel, physiologically-relevant in vitro screening systems (e.g., engineered 3-dimensional or organotypic models) using cells derived from animal species typically utilized for toxicological testing, which will replicate biological interactions and toxicological responses observed in animal tissues or organs, will produce assay data suitable for comparisons between in vitro and in vivo animal toxicology studies, and may ultimately provide alternative methods to reduce the use of animals in toxicity testing.